Oncology
8th Tumor Models San Francisco Summit 2024
Partner Content

8th Tumor Models San Francisco Summit 2024

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie

R&D
5th RNAi-Based Therapeutics Summit
Partner Content

5th RNAi-Based Therapeutics Summit

Despite exciting advancements and new investments into the field, the development of new RNAi therapeutics is plagued by difficulties with extra-hepatic delivery and scale-up of manufacturi